Evidence map›Paper›PMID 41249187›Full record

ArticleNature communications2025

RAF inhibitors activate the integrated stress response by direct activation of GCN2.

Rebecca Gilley, Andrew M Kidger, Graham Neill, Eve Morrison, Paul Severson, Dominic P Byrne, Niall S Kenneth, Gideon Bollag, Chao Zhang, Taiana Maia de Oliveira and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Vitamin B3 suppressesTranslational cancer research · 2026
    Article
  4. BRAFbioRxiv : the preprint server for biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rebecca GilleySignalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. becky.gilley@babraham.ac.uk.
Andrew M KidgerSignalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.ORCID http://orcid.org/0000-0002-3808-0582
Graham NeillDivision of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, UK.
Eve MorrisonSignalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.
Paul SeversonPlexxikon Inc., 1 Bolivar Drive, Berkeley, CA, 94710, USA.ORCID http://orcid.org/0009-0008-6762-6557
Dominic P ByrneDepartment of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7ZB, UK.
Niall S KennethDepartment of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7ZB, UK.ORCID http://orcid.org/0000-0001-8528-1021
Gideon BollagPlexxikon Inc., 1 Bolivar Drive, Berkeley, CA, 94710, USA.
Chao ZhangPlexxikon Inc., 1 Bolivar Drive, Berkeley, CA, 94710, USA.
Taiana Maia de OliveiraMechanistic and Structural Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0000-0003-3231-8112
Patrick A EyersDepartment of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7ZB, UK.ORCID http://orcid.org/0000-0002-9220-2966
Richard BaylissAstbury Centre for Structural Molecular Biology, School of Chemistry, University of Leeds, Leeds, UK.ORCID http://orcid.org/0000-0003-0604-2773
Glenn R MassonDivision of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, UK.ORCID http://orcid.org/0000-0002-1386-4719
Simon J CookSignalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. simon.cook@babraham.ac.uk.ORCID http://orcid.org/0000-0001-9087-1616

Funding

Cancer Research UK (CRUK) C24461/A23302RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/J004456/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/P013384/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/S018514/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/Y006925/1Tenovus T21/01
6 · The paper itself

Abstract

Paradoxical activation of wild type RAF by chemical RAF inhibitors (RAFi) is a well-understood 'on-target' biological and clinical response. In this study, we show that a range of RAFi drive ERK1/2-independent activation of the Unfolded Protein Response (UPR), including expression of ATF4 and CHOP, that requires the translation initiation factor eIF2α. RAFi-induced ATF4 and CHOP expression was not reversed by inhibition of PERK, a known upstream activator of the eIF2α-dependent Integrated Stress Response (ISR). Rather, RAFi exposure activated GCN2, an alternate eIF2α kinase, leading to eIF2α-dependent (and ERK1/2-independent) ATF4 and CHOP expression. The GCN2 kinase inhibitor A-92, GCN2 RNAi, GCN2 knock-out or ISRIB (an eIF2α antagonist) all reversed RAFi-induced expression of ATF4 and CHOP indicating that RAFi require GCN2 to activate the ISR. RAFi also activated full-length recombinant GCN2 in vitro and in cells, generating a characteristic 'bell-shaped' concentration-response curve, reminiscent of RAFi-driven paradoxical activation of WT RAF dimers. Activation of the ISR by RAFi was abolished by a GCN2 kinase dead mutation. A M802A GCN2 gatekeeper mutant was activated at lower RAFi concentrations, demonstrating that RAFi bind directly to the GCN2 kinase domain; this is supported by mechanistic structural models of RAFi interaction with GCN2. Since the ISR is a critical pathway for determining cell survival or death, our observations may be relevant to the clinical use of RAFi, where paradoxical GCN2 activation is a previously unappreciated off-target effect that may modulate tumour cell responses.

Indexed as

Protein Kinase InhibitorsProtein Serine-Threonine Kinasesraf KinasesActivating Transcription Factor 4AnimalseIF-2 KinaseEukaryotic Initiation Factor-2HEK293 CellsHumansMiceStress, PhysiologicalTranscription Factor CHOPUnfolded Protein ResponseActivating Transcription Factor 4ATF4 protein, humanDDIT3 protein, humanEIF2AK4 protein, humanEif2ak4 protein, mouseeIF-2 KinaseEukaryotic Initiation Factor-2Protein Kinase InhibitorsProtein Serine-Threonine Kinasesraf KinasesTranscription Factor CHOP

Identifiers

PMID41249187
PMCPMC12623982

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.